dc.contributor.author | Joerger, M. | en |
dc.contributor.author | Huitema, A. D. R. | en |
dc.contributor.author | Richel, D. J. | en |
dc.contributor.author | Dittrich, C. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Vermorken, J. B. | en |
dc.contributor.author | Strocchi, E. | en |
dc.contributor.author | Martoni, A. | en |
dc.contributor.author | Sorio, R. | en |
dc.contributor.author | Sleeboom, H. P. | en |
dc.contributor.author | Izquierdo, M. A. | en |
dc.contributor.author | Jodrell, D. I. | en |
dc.contributor.author | Calvert, H. | en |
dc.contributor.author | Boddy, A. V. | en |
dc.contributor.author | Hollema, H. | en |
dc.contributor.author | Féty, R. | en |
dc.contributor.author | Vijgh, W. J. F. Van Der | en |
dc.contributor.author | Hempel, G. | en |
dc.contributor.author | Chatelut, E. | en |
dc.contributor.author | Karlsson, M. | en |
dc.contributor.author | Wilkins, J. | en |
dc.contributor.author | Tranchand, B. | en |
dc.contributor.author | Schrijvers, A. H. G. J. | en |
dc.contributor.author | Twelves, C. | en |
dc.contributor.author | Beijnen, J. H. | en |
dc.contributor.author | Schellens, J. H. M. | en |
dc.creator | Joerger, M. | en |
dc.creator | Huitema, A. D. R. | en |
dc.creator | Richel, D. J. | en |
dc.creator | Dittrich, C. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Vermorken, J. B. | en |
dc.creator | Strocchi, E. | en |
dc.creator | Martoni, A. | en |
dc.creator | Sorio, R. | en |
dc.creator | Sleeboom, H. P. | en |
dc.creator | Izquierdo, M. A. | en |
dc.creator | Jodrell, D. I. | en |
dc.creator | Calvert, H. | en |
dc.creator | Boddy, A. V. | en |
dc.creator | Hollema, H. | en |
dc.creator | Féty, R. | en |
dc.creator | Vijgh, W. J. F. Van Der | en |
dc.creator | Hempel, G. | en |
dc.creator | Chatelut, E. | en |
dc.creator | Karlsson, M. | en |
dc.creator | Wilkins, J. | en |
dc.creator | Tranchand, B. | en |
dc.creator | Schrijvers, A. H. G. J. | en |
dc.creator | Twelves, C. | en |
dc.creator | Beijnen, J. H. | en |
dc.creator | Schellens, J. H. M. | en |
dc.date.accessioned | 2018-06-22T09:53:42Z | |
dc.date.available | 2018-06-22T09:53:42Z | |
dc.date.issued | 2007 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41976 | |
dc.description.abstract | Purpose: Paclitaxel and carboplatin are frequently used in advanced ovarian cancer following cytoreductive surgery. Threshold models have been used to predict paclitaxel pharmacokinetic-pharmacodynamics, whereas the time above paclitaxel plasma concentration of 0.05 to 0.2 μmol/L (t C > 0.05-0.2) predicts neutropenia. The objective of this study was to build a population pharmacokinetic-pharmacodynamic model of paclitaxel/carboplatin in ovarian cancer patients. Experimental Design: One hundred thirty-nine ovarian cancer patients received paclitaxel (175 mg/m 2) over 3 h followed by carboplatin area under the concentration-time curve 5 mg/mL*min over 30 min. Plasma concentration-time data were measured, and data were processed using nonlinear mixed-effect modeling. Semiphysiologic models with linear or sigmoidal maximum response and threshold models were adapted to the data. Results: One hundred five patients had complete pharmacokinetic and toxicity data. In 34 patients with measurable disease, objective response rate was 76%. Neutrophil and thrombocyte counts were adequately described by an inhibitory linear response model. Paclitaxel t C > 0.05 was significantly higher in patients with a complete (91.8 h) or partial (76.3 h) response compared with patients with progressive disease (31.5 h; P = 0.02 and 0.05, respectively). Patients with paclitaxel tC > 0.05 > 61.4 h (mean value) had a longer time to disease progression compared with patients with paclitaxel tC > 0.05 0.05 was a good predictor for severe neutropenia (P = 0.01), whereas carboplatin exposure (Cmax and area under the concentration-time curve) was the best predictor for thrombocytopenia (P 0.05 is a good predictive marker for severe neutropenia and clinical outcome, whereas carboplatin exposure is a good predictive marker for thrombocytopenia. ©2007 American Association for Cancer Research. | en |
dc.language.iso | eng | en |
dc.source | Clinical Cancer Research | en |
dc.subject | Europe | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Carboplatin | en |
dc.subject | Disease progression | en |
dc.subject | Drug response | en |
dc.subject | Ovarian neoplasms | en |
dc.subject | Ovary cancer | en |
dc.subject | Paclitaxel | en |
dc.subject | Predictive value of tests | en |
dc.subject | Priority journal | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Diarrhea | en |
dc.subject | Neutropenia | en |
dc.subject | Ondansetron | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Dexamethasone | en |
dc.subject | Treatment outcome | en |
dc.subject | Side effect | en |
dc.subject | Vomiting | en |
dc.subject | Blood toxicity | en |
dc.subject | Nausea | en |
dc.subject | Drug dose reduction | en |
dc.subject | Multiple cycle treatment | en |
dc.subject | Aminotransferase blood level | en |
dc.subject | Granisetron | en |
dc.subject | Ileus | en |
dc.subject | Peripheral neuropathy | en |
dc.subject | Area under curve | en |
dc.subject | Deep vein thrombosis | en |
dc.subject | Clemastine | en |
dc.subject | Drug design | en |
dc.subject | Kinetics | en |
dc.subject | Metoclopramide | en |
dc.subject | Neutrophil count | en |
dc.subject | Pharmacodynamics | en |
dc.subject | Thrombocyte count | en |
dc.title | Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1158/1078-0432.CCR-07-0064 | |
dc.description.volume | 13 | |
dc.description.issue | 21 | |
dc.description.startingpage | 6410 | |
dc.description.endingpage | 6418 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |